TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04192617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 600 mg intravenous (IV)
Study: NCT04192617
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate: 7.5-20 mg/week oral
Study: NCT04060849
Drug: Nozin
Normalized name: Nozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given via nasal single-use popswabs or single-use cotton tipped applicators
Study: NCT04525157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01457131
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days
Study: NCT01604382
Drug: General Anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Anesthesia as described above
Study: NCT01604382
Drug: Neuraxial anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuraxial anesthesia as described above
Study: NCT02931565
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT03437460
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The investigators administer one single 600 mg dose of ibuprofen immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
Study: NCT00767689
Drug: Vitamin B 6
Normalized name: vitamin B 6 100 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin b6 100 mg po daily
Study: NCT00767689
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo is given in the placebo arm
Study: NCT03406689
Drug: Nepafenac 0.1% Oph Susp
Normalized name: NEPAFENAC 0.1% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of Nepafenac 0.1% will be instilled 45' prior to the IVI.
Study: NCT03406689
Drug: Nepafenac 0.3% Oph Susp
Normalized name: NEPAFENAC 0.3% OPH SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of Nepafenac 0.3% will be instilled 45' prior to the IVI.
Study: NCT04158830
Drug: Aspirin 81 mg Enteric Coated Tab - 1 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: take one (1) 81 mg tablet each evening
Study: NCT04158830
Drug: Aspirin 81 mg Enteric Coated Tab - 2 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: take two (2) 81 mg tablets each evening
Study: NCT01927341
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use, 45 mg (three 15 mg tablets), BID
Study: NCT02801448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrine-based placebo without sulforaphane
Study: NCT02547363
Drug: LEO 43204 gel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02616419
Drug: Maxilene® (Lidocaine liposomal 4%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
Study: NCT02547363
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02921360
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00413764
Drug: estradiol-norethisterone
Normalized name: ethinyl estradiol / ethisterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
Study: NCT00315536
Drug: Administration of remifentanil and glycopyrrolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg, intravenius use
Study: NCT03409679
Drug: Two anti-pseudomonal antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
Study: NCT01273779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
Study: NCT04643821
Drug: N-acetylcysteine, NAC, and calcitriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv administration of antioxidant and active vitamin D
Study: NCT03627767
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered as two tablets to be taken orally once daily for 40 weeks
Study: NCT01550471
Drug: Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
Study: NCT01550471
Drug: Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
Study: NCT01550471
Drug: QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
Study: NCT01550471
Drug: QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
Study: NCT01550471
Drug: Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
Study: NCT01550471
Drug: Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
Study: NCT00518973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
Study: NCT02360111
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01933217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00027937
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00316771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po bid
Study: NCT01588639
Drug: Insulin (Scilin R _BAY81-9924
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
Study: NCT04340297
Drug: Acid inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the 1-2 weeks, acid inhibitor (PPI) was reduced from the dose before entering the group to half of the dose, once a day, before going to bed; in the 3-4 weeks, acid inhibitor was changed from PPI to famotidine tablets, 20mg each time, before going to bed; in the 5-6 weeks, all acid inhibitors were stopped.
Study: NCT04340297
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongjiang granules placebo , Jianpi Qinghua granules placebo and Wenpi Qingwei granules placebo. The above three kinds of granulated placebo are respectively made of the simulation containing the low dose original prescription. Taking method is the same as Tongjiang series prescription.
Study: NCT03781544
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
Study: NCT03173027
Drug: Fangji Huangqi pill or Fangji Huangqi pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
Study: NCT01417936
Drug: Sym004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
Study: NCT01843088
Drug: Placebo Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
Study: NCT04547049
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.8 g/m2/day administered IV day -5 through -4.
Study: NCT04145440
Drug: MOR202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
Study: NCT00398827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02188225
Drug: fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/ daily
Study: NCT01400815
Drug: X-22 Smoking Cessation Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period.
Study: NCT03404206
Drug: Naproxen Sodium (Aleve, BAY117031)
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 220 mg x 2 tablets, oral, single dose
Study: NCT03404206
Drug: Ibuprofen (Advil)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg x 2 tablets, oral, single dose
Study: NCT03499171
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is taken once a day as an add-on to PPI treatment (2x/d)
Study: NCT03436654
Drug: GnRH agonist/antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's choice, for a total duration not to extend beyond the treatment phase of the protocol or 10 months from the start of investigational agent(s)
Study: NCT04118933
Drug: JS001
Normalized name: Janus Kinase Inhibitor JS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001 240mg, Q3W
Study: NCT00006324
Drug: Ethinyl estradiol/levonorgestrel
Normalized name: ETHINYL ESTRADIOL/LEVONORGESTREL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00638859
Drug: Telithromycin (HMR3647)
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00857415
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
Study: NCT06185127
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bolus doses of fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 150 μg of fentanyl were administered.
Study: NCT01199731
Drug: GSK2248761 100 mg once daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 100mg capsule OAD plus matching placebo
Study: NCT00756847
Drug: XL147 (SAR245408),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
Study: NCT02789111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily up to 15 doses
Study: NCT01336296
Drug: mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
Study: NCT02071927
Drug: CB-839
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent CB-839
Study: NCT02071927
Drug: CB-Aza
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB-839 in combination with standard dose azacitidine
Study: NCT01701778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline
Study: NCT00931853
Drug: SENNA+CASSIA(Naturetti)
Normalized name: Padang cassia oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
Study: NCT03635684
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infusion of Acetaminophen over 20 to 30 minutes, with evaluation of:~* local side effects;~* pain and/or fever;~at time of infusion, after 30 minutes, 60 minutes and 180 minutes.
Study: NCT00125567
Drug: Levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
Study: NCT00698425
Drug: Citrate buffer
Normalized name: Citrate Buffer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
Study: NCT03439943
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).
Study: NCT00557401
Drug: XP19986 SR3, 20 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
Study: NCT00557401
Drug: XP19986 SR3, 40 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
Study: NCT00557401
Drug: XP19986 SR3, 60 mg QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
Study: NCT00557401
Drug: XP19986 SR3, 30 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.
Study: NCT00557401
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken orally for approximately 32 days with titration and taper periods.
Study: NCT04133480
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution of 100 milligrams per milliliter (mg/mL) cannabidiol (CBD)
Study: NCT00319449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin
Study: NCT00455533
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
Study: NCT00455533
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
Study: NCT01437878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01715714
Drug: Statin Recapture Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given 12h and 2h before CABG
Study: NCT01715714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given 12h and 2h before CABG.
Study: NCT06304038
Drug: Flu Vaccine
Normalized name: flu vaccine 2012 (18-64yrs)/PF 27 mcg/0.1 mL INTRADERM SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra
Study: NCT03539354
Drug: B-blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standart b-blocker therapy will be administered in each group for AF prophylactics
Study: NCT00681408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil placebo pills
Study: NCT00923936
Drug: Liposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles.
Study: NCT04483167
Drug: 99mTccAbVCAM1-5 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection of 99mTccAbVCAM1-5 with dose increase
Study: NCT02066220
Drug: Reduced-intensity maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.~Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2.
Study: NCT00077428
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02330679
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention will consist of a 2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine (a SNRI medication)
Study: NCT02066220
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients).
Study: NCT02066220
Drug: Induction Chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 37,5mg/m² in 24h-infusion, days 1 and 2 (If administration of doxorubicin is not deemed appropriate, doxorubicin can be substituted by carboplatin 200mg/m²) VCR 1,5mg/m² (max. dose 2mg) in short infusion, days 1, 15, 29, 43 HD-MTX 5g/m²in two doses (0.5g/m² in 0.5h and 4.5g/m² in 23.5h), days 15 and 29 (+ Leucovorin) Carboplatin 200mg/m² in 1h-infusion, days 43, 44, and 45 MTX 2mg intraventricularly, days 1-4, 15, 16, 29, 30, 43-46
Study: NCT04689958
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin, pregabalin, or amitriptyline
Study: NCT01422733
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10mg/m2/per day PO at bedtime (X12 weeks)
Study: NCT01422733
Drug: rhCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mcg IV twice
Study: NCT02066220
Drug: Vinblastin Maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly VBL (5mg/m², max. 10mg/dose) for 24 weeks
Study: NCT00969813
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 10 mg dose of CP-690,550
Study: NCT04075110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily
Study: NCT02265952
Drug: REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled participants received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Participants were followed for a period of 24 weeks (through Week 26 \[Day 183\]) after the last dose of study drug in the main study period.
Study: NCT02038452
Drug: Depo-Medrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid Injection
Study: NCT00859183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral
Study: NCT01706198
Drug: inhaled corticosteroid with or without a long acting beta2-agonist
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS alone or in combination with a long acting bronchodilator